These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 19305756)

  • 1. Costs of new atypical antipsychotic agents for schizophrenia: does unrestricted access reduce hospital utilization?
    O'Reilly D; Craig D; Phillips L; Goeree R; Tarride JE; Parfrey P
    Healthc Policy; 2007 Aug; 3(1):58-79. PubMed ID: 19305756
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The unintended (and costly) effects due to the introduction of an unrestricted reimbursement policy for atypical antipsychotic medications in a Canadian public prescription drug program: 1996/97 to 2005/06.
    O'Reilly DJ; Goeree RA; Tarride JE; James C; Parfrey PS
    Can J Clin Pharmacol; 2009; 16(2):e346-59. PubMed ID: 19531813
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].
    Llorca PM; Miadi-Fargier H; Lançon C; Jasso Mosqueda G; Casadebaig F; Philippe A; Guillon P; Mehnert A; Omnès LF; Chicoye A; Durand-Zaleski I
    Encephale; 2005; 31(2):235-46. PubMed ID: 15959450
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness and cost of atypical versus typical antipsychotic treatment for schizophrenia in routine care.
    Stargardt T; Weinbrenner S; Busse R; Juckel G; Gericke CA
    J Ment Health Policy Econ; 2008 Jun; 11(2):89-97. PubMed ID: 18509216
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of changes in utilization of health-care services after implementation of a prior authorization policy for atypical antipsychotic agents.
    Walthour A; Seymour L; Tackett R; Perri M
    Ann Pharmacother; 2010 May; 44(5):809-18. PubMed ID: 20388858
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hospitalization resource utilization and costs among Medicaid insured patients with schizophrenia with different treatment durations of long-acting injectable antipsychotic therapy.
    Bera R; Offord S; Zubek D; Lau G; Lin J; Karson C
    J Clin Psychopharmacol; 2014 Feb; 34(1):30-5. PubMed ID: 24135840
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of adjunctive mood stabilizers on antipsychotic utilization pattern and health resource utilization for Medicaid enrollees with schizophrenia.
    Chen H; Kennedy WK; Dorfman JH; Fincham JE; Reeves J; Martin BC
    Curr Med Res Opin; 2007 Jun; 23(6):1351-65. PubMed ID: 17559734
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment Patterns, Healthcare Resource Utilization and Costs Among Schizophrenia Patients Treated with Long-Acting Injectable Versus Oral Antipsychotics.
    Shah A; Xie L; Kariburyo F; Zhang Q; Gore M
    Adv Ther; 2018 Nov; 35(11):1994-2014. PubMed ID: 30269292
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Retrospective assessment of Medicaid step-therapy prior authorization policy for atypical antipsychotic medications.
    Farley JF; Cline RR; Schommer JC; Hadsall RS; Nyman JA
    Clin Ther; 2008 Aug; 30(8):1524-39; discussion 1506-7. PubMed ID: 18803994
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Which Clinical and Patient Factors Influence the National Economic Burden of Hospital Readmissions After Total Joint Arthroplasty?
    Kurtz SM; Lau EC; Ong KL; Adler EM; Kolisek FR; Manley MT
    Clin Orthop Relat Res; 2017 Dec; 475(12):2926-2937. PubMed ID: 28108823
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Health care resource utilization and direct medical costs for patients with schizophrenia initiating treatment with atypical versus typical antipsychotics in Tianjin, China.
    He X; Wu J; Jiang Y; Liu L; Ye W; Xue H; Montgomery W
    BMC Health Serv Res; 2015 Apr; 15():149. PubMed ID: 25880803
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of incremental healthcare resource burden and readmission rates associated with hospitalized hyponatremic patients in the US.
    Amin A; Deitelzweig S; Christian R; Friend K; Lin J; Belk K; Baumer D; Lowe TJ
    J Hosp Med; 2012 Oct; 7(8):634-9. PubMed ID: 22961813
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Estimating the Impact of Adherence to and Persistence with Atypical Antipsychotic Therapy on Health Care Costs and Risk of Hospitalization.
    Jiang Y; Ni W
    Pharmacotherapy; 2015 Sep; 35(9):813-22. PubMed ID: 26406773
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Review and analysis of hospitalization costs associated with antipsychotic nonadherence in the treatment of schizophrenia in the United States.
    Sun SX; Liu GG; Christensen DB; Fu AZ
    Curr Med Res Opin; 2007 Oct; 23(10):2305-12. PubMed ID: 17697454
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of early nonadherence to oral antipsychotics on clinical and economic outcomes among patients with schizophrenia.
    Offord S; Lin J; Mirski D; Wong B
    Adv Ther; 2013 Mar; 30(3):286-97. PubMed ID: 23483449
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Schizophrenia and schizoaffective disorder: Length of stay and associated factors.
    Goga LY; Marais BS
    S Afr J Psychiatr; 2024; 30():2237. PubMed ID: 38726337
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomised controlled trials of conventional antipsychotic versus new atypical drugs, and new atypical drugs versus clozapine, in people with schizophrenia responding poorly to, or intolerant of, current drug treatment.
    Lewis SW; Davies L; Jones PB; Barnes TR; Murray RM; Kerwin R; Taylor D; Hayhurst KP; Markwick A; Lloyd H; Dunn G
    Health Technol Assess; 2006 May; 10(17):iii-iv, ix-xi, 1-165. PubMed ID: 16707074
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Healthcare resource usage of schizophrenia patients initiating long-acting injectable antipsychotics vs oral.
    Offord S; Wong B; Mirski D; Baker RA; Lin J
    J Med Econ; 2013; 16(2):231-9. PubMed ID: 23163287
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Healthcare utilization and costs of Veterans Health Administration patients with schizophrenia treated with paliperidone palmitate long-acting injection or oral atypical antipsychotics.
    Baser O; Xie L; Pesa J; Durkin M
    J Med Econ; 2015 May; 18(5):357-65. PubMed ID: 25525771
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of a limiting Medicaid drug-reimbursement benefits on the use of psychotropic agents and acute mental health services by patients with schizophrenia.
    Soumerai SB; McLaughlin TJ; Ross-Degnan D; Casteris CS; Bollini P
    N Engl J Med; 1994 Sep; 331(10):650-5. PubMed ID: 8052275
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.